CommercialCoverageLow impact
08.02.46, Zevaskyn™ (prademagene zamikeracel)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
A new policy for Zevaskyn™ (prademagene zamikeracel) has been established under policy number 08.02.46 in the Pharmacy category. This appears to be a new drug coverage policy that was both posted and removed on the same day (04/01/2026), suggesting it may be a template or placeholder policy.
Action Required
Monitor for updated policy details: Since this policy was posted and removed on the same day, billing team should watch for a revised version of policy 08.02.46 for Zevaskyn™. Contact payer for clarification on coverage criteria and billing requirements when this drug becomes available.